Pancreatic cancer
Conditions
Interventions
experimental group:Nimotuzumab combined with PD-1, Tiggio, gemcitabine
Sponsors
Baotou Cancer Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. The first diagnosis of locally advanced or metastatic pancreatic cancer, and the need for puncture or biopsy is pathologically confirmed as pancreatic cancer, or pathological diagnosis cannot be obtained. After MDT discussion, the clinical diagnosis of pancreatic cancer is considered, with or without immunohistochemical examination of EGFR expression or Genetic testing of K-RAS mutations can be done. 2. Have not received special treatment such as radiotherapy and chemotherapy before. 3. Good physical condition: (1) ECOG score <= 2 points; (2) Pain control is good, pain numerical grading (NRS) evaluation value <= 3; (3) Biliary tract is unobstructed (such as obstructive jaundice, current bile duct stent implantation); (4) Stable weight. 4. Aged 18-80 years, voluntarily join the clinical trial and sign the informed consent form, with high compliance.
Exclusion criteria
Exclusion criteria: 1. Patients receiving any radiotherapy or chemotherapy or participating in other clinical trials; 2. Have a history of major surgery in the past 3 weeks; 3. Patients with severe underlying diseases: including severe cardiovascular and cerebrovascular diseases, abnormal liver, kidney, and respiratory functions; 4. Cannot tolerate the side effects of chemotherapy drugs. 5. Patients have poor compliance and cannot cooperate with treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival (OS);Progression-free survival (PFS);Objective response rate (ORR);Adverse reactions; | — |
Countries
China
Contacts
Public ContactYa-Qin Tam, Jie Li
Baotou Cancer Hospital
Outcome results
None listed